The FDA recently approved teriparatide (rDNA origin) injection [Forteo, Eli Lilly], a recombinant form of human parathyroid hormone, for the treatment of postmenopausal women with osteoporosis who are at increased risk for fracture. Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.